


Please type a plus sign (+) inside this box → 

PTO/SB/08A/8 (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Complete if Known		
			Application Number	10/615,329	
			Filing Date	July 8, 2003	
			First Named Inventor	HASHIMOTO, Hiromasa	
			Group Art Unit	1624	
			Examiner Name	Z. TVCKER	
Sheet	1	of	3	Attorney Docket Number	223488


U.S. PATENT DOCUMENTS								
Examiner Initials ¹	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Class	Subclass	Filing Date if Appropriate
		Patent Number	Kind Code					
ZT	AA	3,644,382		Clemence et al.	12-22-1972			
ZT	AB	3,778,504		Clemence et al.	12-11-1973			
ZT	AC	4,250,317		Meyer et al.	02-10-1981			
ZT	AD	4,360,679		Meyer et al.	11-23-1982			
ZT	AE	5,280,030		Jegham et al.	01-18-1994			
ZT	AF	5,563,143		Cohan et al.	10-08-1996			
ZT	AG	5,633,388		Diana et al.	05-27-1997			
ZT	AH	5,814,651		Duplantier et al.	09-29-1998			
ZT	AI	5,998,398		Daluge et al.	12-07-1999			
ZT	AJ	6,166,219		Yamasaki et al.	12-26-2000			
ZT	AK	6,211,177		Sperl et al.	04-03-2001			
ZT	AL	6,448,281		Beaulieu et al.	09-10-2002			

(NOT PRIOR ART)


FOREIGN PATENT DOCUMENTS										
Examiner Initials ¹	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Class	Subclass	Translation	
		Office	Number	Kind Code					Yes	No*
ZT	AM	EP	0 010 063	A	CIBA Geigy AG	04-16-1980				X ⁺
ZT	AN	EP	0 507 650	A	Synthelabo	10-07-1992				X ⁺
ZT	AO	EP	0 694 535	A	Eli Lilly and Company	01-31-1996				
ZT	AP	JP	03 031264	A	Otsuka Seiyaku Kogyo KK	02-12-1991				X ⁺
ZT	AQ	JP	06-025182	A	Kanebo Ltd	02-01-1994				X ⁺
ZT	AR	WO	96/07646	A	Wellcome Foundation	03-14-1996				
ZT	AS	WO	96/35713	A	Pfizer, Inc.	11-14-1996				

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner SigNat.		Date Considered	19 JUNE 2007
------------------	---	-----------------	--------------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please type a plus sign (+) inside this box → 

PTO/SB/08A/B (10-98)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/615,329
				Filing Date	July 8, 2003
				First Named Inventor	HASHIMOTO, Hiromasa
				Group Art Unit	1624
				Examiner Name	Z. TVCKER
Sheet	2	of	3	Attorney Docket Number	223488

FOREIGN PATENT DOCUMENTS										
Examiner Initials ¹	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Class	Subclass	Translation	
		Office	Number	Kind Code					Yes	No*
ZT	AT	WO	97/25316	A	Glaxo Group Limited	07-17-1997				
ZT	AU	WO	97/41884	A	Pharma Pacific Pty.	11-13-1997				
ZT	AV	WO	97/46237	A	Eli Lilly and Company	12-11-1997				
ZT	AW	WO	98/05327	A	Rhône-Poulenc Rorer	02-12-1998				
ZT	AX	WO	98/37072	A	U.S. Dept. Health & Human Services	08-27-1998				
ZT	AY	WO	98/50029	A	Univ. of Pittsburgh	11-12-1998				
ZT	AZ	WO	98/50030	A	Univ. of Pittsburgh	11-12-1998				
ZT	BA	WO	98/50031	A	Univ. of Pittsburgh	11-12-1998				
ZT	BB	WO	99/24060	A	Mayo Foundation	05-20-1999				
ZT	BC	WO	99/51619	A	University of Michigan	10-14-1999				
ZT	BD	WO	01/21634	A	Trega Biosciences, Inc.	03-29-2001				
ZT	BE	WO	01/47883	A	Japan Tobacco Inc.	07-05-2001				X ⁺
ZT	BF	WO	02/04425	A	Boehringer Ingelheim (Canada) Ltd.	01-17-2002				

OTHER - NON PATENT LITERATURE DOCUMENTS									
Examiner Initials ¹	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation						
			Yes	No*					
ZT	BG	BEHRENS et al., <i>EMBO J.</i> , 15 (1), 12-22 (1996)							
ZT	BH	HASKELL et al., <i>J. Med. Chem.</i> , 13 (4), 697-704 (1970)							
ZT	BI	HORI et al., <i>Chem. Pharm. Bull.</i> , 41 (10), 1832-1841 (1993)							
ZT	BJ	KATAEV et al., <i>Khimiko-Farmatsevticheskii Zhurnal</i> , 30 (7), 22-24 (1996)		X ⁺					
ZT	BK	KATAEV et al., <i>Pharmaceutical Chemistry Journal</i> , 30 (7), 448-450 (1996)							

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner SigNat.		Date Considered	19 JUNE 2007
------------------	---	-----------------	--------------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

+

PTO/SB/08A/B (10-96)

Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

OTHER - NON PATENT LITERATURE DOCUMENTS

* A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).

+ An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).

Examiner
SigNat.

Date _____

Considered

19 JUNE 2007

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.